Merck Backs Up Keytruda Approval In TNBC With Encouraging Overall Survival Data
Merck & Co Inc (NYSE: MRK) announced the final overall survival (OS) results from the Phase 3 KEYNOTE-355 trial of Keytruda in combination with chemotherapy for the first-line metastatic triple-negative breast cancer (mTNBC).
Keytruda combined with chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine/carboplatin) demonstrated a statistically significant and clinically meaningful improvement in OS.
The data were presented at the European Society for Medical Oncology (ESMO21) Congress 2021.
A combination of Keytruda and chemotherapy reduced the risk of death by 27% over Chemo alone in previously untreated patients whose tumors expressed the PD-L1 biomarker at a combined positive score (CPS) of at least 10.
Adding Keytruda helped the patients live an additional 6.9 months or a median of 23 months versus 16.1 months in the Chemo alone group.
Keytruda snagged an accelerated approval in front-line triple-negative breast cancer in November.
In July, an FDA green light for its use around surgery for early-stage, high-risk TNBC converted that conditional nod into a full one.
Related Link: FDA Approves Merck's Keytruda/Chemo Combo For Early Breast Cancer.
Price Action: MRK shares are down 0.95% at $71.00 during the premarket session on the last check Monday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).
See more from Benzinga
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
